Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment ConferenceBusiness Wire • 08/28/23
Xeris Biopharma achieves record 2Q revenue and tightens full-year guidanceProactive Investors • 08/08/23
Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023Business Wire • 08/01/23
Xeris Biopharma achieves shipping milestone for hypoglycemia treatment GvokeProactive Investors • 07/31/23
Xeris Biopharma says first participant dosed in Phase 2 clinical study of investigational subcutaneous levothyroxine in patients with hypothyroidismProactive Investors • 06/21/23
Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With HypothyroidismBusiness Wire • 06/21/23
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023Business Wire • 05/02/23
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ FormulationsBusiness Wire • 04/18/23
Xeris Biopharma announces research evaluation collaboration and option agreement with Regeneron for XeriJectProactive Investors • 03/30/23
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™Business Wire • 03/30/23
Xeris Biopharma appoints brand management expert Ricki Fairley to its board of directorsProactive Investors • 03/29/23